Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial

被引:23
作者
Jorgensen, M. E. [1 ]
Torp-Pedersen, C. [2 ]
Finer, N. [3 ]
Caterson, I. [4 ]
James, W. P. T. [5 ]
Legler, U. F. [6 ]
Andersson, C. [1 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-1168 Copenhagen, Denmark
[2] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark
[3] UCL, Inst Cardiovasc Sci, Ctr Cardiovasc Prevent & Outcomes, London, England
[4] Univ Sydney, Boden Inst, Sydney, NSW 2006, Australia
[5] London Sch Hyg & Trop Med, London WC1, England
[6] Special Vocat Coll Handicapped Persons, Mainz, Germany
关键词
SCOUT; Bilirubin; Cardiovascular disease; ISCHEMIC-HEART-DISEASE; UGT1A1-ASTERISK-28; ALLELE; GILBERT-SYNDROME; SIBUTRAMINE; OUTCOMES; OBESE; LEVEL;
D O I
10.1016/j.numecd.2013.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: An inverse relationship between (serum) total bilirubin and risk of cardiovascular disease has been reported previously, but longitudinal data on overweight and obese patients are lacking. We have investigated the relationship between total bilirubin and cardiovascular adverse events in a large group of patients with risk factors for cardiovascular disease who were enrolled in a large weight loss trial. Methods and results: Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. The relationship between total bilirubin level at screening and the primary outcome (i.e. non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death) for the entire study period was investigated using Cox proportional hazards models. The population was divided into four groups based on total bilirubin levels (normal range 5-25 mu mol/L). Time-dependent Cox analyses were also performed to adjust for weight loss over time. Initial analyses adjusted for sex, age and treatment allocation showed significantly reduced hazard ratios of 0.80 (95% confidence interval 0.68-0.94), 0.73 (0.62-0.86) and 0.77 (0.65-0.91), for the three higher total bilirubin groups: >8 and <= 10 mu mol/L, >10 and <= 13 mu mol/L and >13 mu mol/L (5-95 interpercentile range for total bilirubin at screening; 6-19 mu mol/L), compared to the lowest total bilirubin group <= 8 mu mol/L. When adjusting for classical cardiovascular risk factors, estimates increased towards unity. Additional adjustment for indicators of liver function did not alter the results. A time-dependent Cox model, adjusted for weight loss, demonstrated a similar trend. Conclusion: Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population. (C) 2014 Elsevier B. V. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 19 条
[1]   Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial [J].
Andersson, Charlotte ;
Weeke, Peter ;
Fosbol, Emil Loldrup ;
Brendorp, Bente ;
Kober, Lars ;
Coutinho, Walmir ;
Sharma, Arya M. ;
Van Gaal, Luc ;
Finer, Nick ;
James, W. Philip T. ;
Caterson, Ian D. ;
Rode, Richard A. ;
Torp-Pedersen, Christian .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (08) :1109-1115
[2]  
BREIMER LH, 1995, CLIN CHEM, V41, P1504
[3]   Improved resistance to serum oxidation in Gilbert's syndrome: A mechanism for cardiovascular protection [J].
Bulmer, Andrew C. ;
Blanchfield, Joanne T. ;
Toth, Istvan ;
Fassett, Robert G. ;
Coornbes, Jeff S. .
ATHEROSCLEROSIS, 2008, 199 (02) :390-396
[4]   Total serum bilirubin and risk of cardiovascular disease in the Framingham Offspring Study [J].
Djoussé, L ;
Levy, D ;
Cupples, LA ;
Evans, JC ;
D'Agostino, RB ;
Ellison, RC .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10) :1196-+
[5]   Cardiovascular Events as a Function of Serum Bilirubin Levels in a Large, Statin-Treated Cohort [J].
Horsfall, Laura J. ;
Nazareth, Irwin ;
Petersen, Irene .
CIRCULATION, 2012, 126 (22) :2556-2564
[6]   Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects [J].
James, W. Philip T. ;
Caterson, Ian D. ;
Coutinho, Walmir ;
Finer, Nick ;
Van Gaal, Luc F. ;
Maggioni, Aldo P. ;
Torp-Pedersen, Christian ;
Sharma, Arya M. ;
Shepherd, Gillian M. ;
Rode, Richard A. ;
Renz, Cheryl L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) :905-917
[7]   Low Serum Bilirubin Level as an Independent Predictor of Stroke Incidence A Prospective Study in Korean Men and Women [J].
Kimm, Heejin ;
Yun, Ji Eun ;
Jo, Jaeseong ;
Jee, Sun Ha .
STROKE, 2009, 40 (11) :3422-3427
[8]   Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham heart study [J].
Lin, Jing-Ping ;
O'Donnell, Christopher J. ;
Schwaiger, Johannes P. ;
Cupples, L. Adrienne ;
Lingenhel, Arno ;
Hunt, Steven C. ;
Yang, Song ;
Kronenberg, Florian .
CIRCULATION, 2006, 114 (14) :1476-1481
[9]   Serum Bilirubin and Genes Controlling Bilirubin Concentrations as Biomarkers for Cardiovascular Disease [J].
Lin, Jing-Ping ;
Vitek, Libor ;
Schwertner, Harvey A. .
CLINICAL CHEMISTRY, 2010, 56 (10) :1535-1543
[10]   The biliverdin-bilirubin antioxidant cycle of cellular protection: Missing a wheel? [J].
McDonagh, Antony F. .
FREE RADICAL BIOLOGY AND MEDICINE, 2010, 49 (05) :814-820